In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection

Atherosclerosis

Volumn 206, Issue 2, 2009, Pages 321-327

  Escolà Gil, Joan Carles ^a,b   Rotllan, Noemí ^a   Julve, Josep ^b   Blanco Vaca, Francisco ^a,b,c  

^a Institut de Recerca   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Antioxidant enzymes; Atherosclerosis; HDL; Macrophages; Reverse cholesterol transport

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ABC TRANSPORTER A1; ABC TRANSPORTER G1; ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN M; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CHOLESTEROL ESTERASE; ETC 216; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID TRANSFER PROTEIN; LIVER X RECEPTOR AGONIST; NICOTINIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; SCAVENGER RECEPTOR BI; SECRETORY PHOSPHOLIPASE A2; SPHINGOLIPID; TORCETRAPIB; TRIACYLGLYCEROL LIPASE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY THROMBOSIS; ATHEROSCLEROSIS; CELL ASSAY; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DISEASE MODEL; DISEASE PREDISPOSITION; HUMAN; HYPERTENSION; IN VIVO STUDY; MACROPHAGE; MEASUREMENT; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD36; ANTIOXIDANTS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; HUMANS; LIPASE; LIPOPROTEINS; MACROPHAGES; MICE; MICE, TRANSGENIC; ORPHAN NUCLEAR RECEPTORS; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEINS;

EID: 70349434883     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.12.044     Document Type: Review

References (70)

1. Rader D.J. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116 (2006) 3090-3100
2. Chiesa G., and Sirtori C.R. Apolipoprotein A-I(Milano): current perspectives. Curr Opin Lipidol 14 (2003) 159-163
3. Navab M., Anantharamaiah G.M., Reddy S.T., et al. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2 (2006) 504-511
4. deGoma E.M., deGoma R.L., and Rader D.J. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 51 (2008) 2199-2211
5. Escola-Gil J.C., Calpe-Berdiel L., Palomer X., et al. Antiatherogenic role of high-density lipoproteins: insights from genetically engineered-mice. Front Biosci 11 (2006) 1328-1348
6. Cuchel M., and Rader D.J. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation 113 (2006) 2548-2555
7. Norata G.D., Callegari E., Marchesi M., et al. High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 111 (2005) 2805-2811
8. Ferretti G., Bacchetti T., Negre-Salvayre A., et al. Structural modifications of HDL and functional consequences. Atherosclerosis 184 (2006) 1-7
9. Norata G.D., Pirillo A., and Catapano A.L. Modified HDL: biological and physiopathological consequences. Nutr Metab Cardiovasc Dis 16 (2006) 371-386
10. Navab M., Ananthramaiah G.M., Reddy S.T., et al. The double jeopardy of HDL. Ann Med 37 (2005) 173-178
11. Calpe-Berdiel L., Rotllan N., Palomer X., et al. Direct evidence in vivo of impaired macrophage-specific reverse cholesterol transport in ATP-binding cassette transporter A1-deficient mice. Biochim Biophys Acta 1738 (2005) 6-9
12. Wang M.D., Franklin V., and Marcel Y.L. In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired. Arterioscler Thromb Vasc Biol 27 (2007) 1837-1842
13. Wang X., Collins H.L., Ranalletta M., et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 117 (2007) 2216-2224
14. Mukhamedova N., Escher G., D'Souza W., et al. Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo. J Lipid Res 49 (2008) 2312-2322
15. Pennings M., Meurs I., Ye D., et al. Regulation of cholesterol homeostasis in macrophages and consequences for atherosclerotic lesion development. FEBS Lett 580 (2006) 5588-5596
16. Out R., Hoekstra M., Hildebrand R.B., et al. Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 26 (2006) 2295-2300
17. Ranalletta M., Wang N., Han S., et al. Decreased atherosclerosis in low-density lipoprotein receptor knockout mice transplanted with Abcg1-/- bone marrow. Arterioscler Thromb Vasc Biol 26 (2006) 2308-2315
18. Baldan A., Pei L., Lee R., et al. Impaired development of atherosclerosis in hyperlipidemic Ldlr-/- and ApoE-/- mice transplanted with Abcg1-/- bone marrow. Arterioscler Thromb Vasc Biol 26 (2006) 2301-2307
19. Out R., Jessup W., Le Goff W., et al. Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1. Circ Res 102 (2008) 113-120
20. Yvan-Charvet L., Ranalletta M., Wang N., et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 117 (2007) 3900-3908
21. Out R., Hoekstra M., Habets K., et al. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler Thromb Vasc Biol 28 (2008) 258-264
22. Huby T., Doucet C., Dachet C., et al. Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues. J Clin Invest 116 (2006) 2767-2776
23. Van Eck M., Hoekstra M., Hildebrand R.B., et al. Increased oxidative stress in scavenger receptor BI knockout mice with dysfunctional HDL. Arterioscler Thromb Vasc Biol 27 (2007) 2413-2419
24. Zhao B., Song J., Chow W.N., et al. Macrophage-specific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr mice. J Clin Invest 117 (2007) 2983-2992
25. Moore R.E., Navab M., Millar J.S., et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 97 (2005) 763-771
26. Castellani L.W., Navab M., Van Lenten B.J., et al. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest 100 (1997) 464-474
27. Ribas V., Sanchez-Quesada J.L., Anton R., et al. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ Res 95 (2004) 789-797
28. Blanco-Vaca F., Escola-Gil J.C., Martin-Campos J.M., et al. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res 42 (2001) 1727-1739
29. Rotllan N., Ribas V., Calpe-Berdiel L., et al. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 25 (2005) e128-132
30. Escola-Gil J.C., Julve J., Martin-Campos J.M., et al. Apolipoprotein A-II. In: Fielding C.J. (Ed). High-density lipoproteins: from basic biology to clinical aspects (2007), Wiley-VCH 25-41
31. Nofer J.R., and Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med 15 (2005) 265-271
32. Nofer J.R., Bot M., Brodde M., et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 115 (2007) 501-508
33. Getz G.S., and Reardon C.A. Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 15 (2004) 261-267
34. Ng C.J., Hama S.Y., Bourquard N., et al. Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice. Mol Genet Metab 89 (2006) 368-373
35. Ng C.J., Bourquard N., Grijalva V., et al. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem 281 (2006) 29491-29500
36. Ng C.J., Bourquard N., Hama S.Y., et al. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27 (2007) 1368-1374
37. Noto H., Hara M., Karasawa K., et al. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 23 (2003) 829-835
38. Quarck R., De Geest B., Stengel D., et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103 (2001) 2495-2500
39. Chen C.H. Platelet-activating factor acetylhydrolase: is it good or bad for you?. Curr Opin Lipidol 15 (2004) 337-341
40. Asztalos B.F., Schaefer E.J., Horvath K.V., et al. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J Lipid Res 48 (2007) 592-599
41. Stein O., and Stein Y. Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis 178 (2005) 217-230
42. Leitinger N., Watson A.D., Hama S.Y., et al. Role of group II secretory phospholipase A2 in atherosclerosis: 2 Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol 19 (1999) 1291-1298
43. Wolfrum C., Poy M.N., and Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 11 (2005) 418-422
44. Christoffersen C., Jauhiainen M., Moser M., et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem 283 (2008) 1839-1847
45. Harada L.M., Amigo L., Cazita P.M., et al. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion. Atherosclerosis 191 (2007) 313-318
46. Tanigawa H., Billheimer J.T., Tohyama J., et al. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation 116 (2007) 1267-1273
47. Rotllan N., Calpe-Berdiel L., Guillaumet-Adkins A., et al. CETP activity variation in mice does not affect two major HDL antiatherogenic properties: macrophage-specific reverse cholesterol transport and LDL antioxidant protection. Atherosclerosis 196 (2008) 505-513
48. Cazita P.M., Berti J.A., Aoki C., et al. Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice. J Lipid Res 44 (2003) 33-40
49. Westerterp M., van der Hoogt C.C., de Haan W., et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 26 (2006) 2552-2559
50. Lie J., de Crom R., van Gent T., et al. Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. J Lipid Res 45 (2004) 805-811
51. Ishida T., Choi S.Y., Kundu R.K., et al. Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice. J Biol Chem 279 (2004) 45085-45092
52. Ko K.W., Paul A., Ma K., et al. Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE-/- and LDLR-/- mice. J Lipid Res 46 (2005) 2586-2594
53. Jin W., Wang X., Millar J.S., et al. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab 6 (2007) 129-136
54. Trigatti B.L., Krieger M., and Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003) 1732-1738
55. Zhang Y., Da Silva J.R., Reilly M., et al. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest 115 (2005) 2870-2874
56. Yu L., Hammer R.E., Li-Hawkins J., et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci U S A 99 (2002) 16237-16242
57. Calpe-Berdiel L., Rotllan N., Fievet C., et al. Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ABCG5/G8. J Lipid Res 49 (2008) 1904-1911
58. Wilund K.R., Yu L., Xu F., et al. No association between plasma levels of plant sterols and atherosclerosis in mice and men. Arterioscler Thromb Vasc Biol 24 (2004) 2326-2332
59. Salen G., Shefer S., Nguyen L., et al. Sitosterolemia. J Lipid Res 33 (1992) 945-955
60. Temel R.E., Tang W., Ma Y., et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 117 (2007) 1968-1978
61. Navab M., Anantharamaiah G.M., Reddy S.T., et al. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 3 (2006) 540-547
62. Singh I.M., Shishehbor M.H., and Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298 (2007) 786-798
63. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
64. Tardif J.C., Gregoire J., L'Allier P.L., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007) 1675-1682
65. Schaefer E.J., and Asztalos B.F. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. Am J Cardiol 100 (2007) n25-31
66. Navab M., Anantharamaiah G.M., Reddy S.T., et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109 (2004) 3215-3220
67. Navab M., Anantharamaiah G.M., Hama S., et al. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 25 (2005) 1426-1432
68. Bloedon L.T., Dunbar R.L., Duffy D., et al. Oral administration of the apolipoprotein A-1 mimetic peptide D-4F in humans with CHD improves HDL anti-inflammatory function after a single dose. Circulation 114 (2006) 288
69. Naik S.U., Wang X., Da Silva J.S., et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 113 (2006) 90-97
70. Zanotti I., Poti F., Pedrelli M., et al. The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. J Lipid Res 49 (2008) 954-960